Literature DB >> 9366436

Two functionally independent pathways for lipopolysaccharide-dependent activation of mouse peritoneal macrophages.

C R Amura1, L C Chen, N Hirohashi, M G Lei, D C Morrison.   

Abstract

We have investigated the effects of human LPS-binding protein (LBP) and human bactericidal/permeability-increasing protein (BPI) on LPS-dependent activation of mouse thioglycolate-elicited peritoneal macrophages in vitro, in comparison with human PBMCs. Confirming earlier published studies, BPI inhibited, and LBP enhanced, the ability of LPS to stimulate PBMC production of the cytokines TNF-alpha and IL-6. In marked contrast to these results, under identical conditions of in vitro culture, both LBP and BPI suppressed, in a dose-dependent manner, the ability of LPS to stimulate cytokine production in mouse macrophages. Further, while human BPI also suppressed LPS-dependent NO secretion in mouse macrophages, human LBP had no inhibitory effect on NO secretion under conditions that inhibited TNF-alpha secretion. These data provide the first direct evidence that mouse macrophages may utilize two independent pathways in response to LPS, thus leading to different phenotypic responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366436

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.

Authors:  A A Khan; L H Lambert; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Regulation of cellular caveolin-1 protein expression in murine macrophages by microbial products.

Authors:  Mei G Lei; Xiaoyu Tan; Nilofer Qureshi; David C Morrison
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.

Authors:  N Lamping; R Dettmer; N W Schröder; D Pfeil; W Hallatschek; R Burger; R R Schumann
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Lipopolysaccharide and its analog antagonists display differential serum factor dependencies for induction of cytokine genes in murine macrophages.

Authors:  P Y Perera; N Qureshi; W J Christ; P Stütz; S N Vogel
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Redox imbalance differentially inhibits lipopolysaccharide-induced macrophage activation in the mouse liver.

Authors:  F Wang; L Y Wang; D Wright; M J Parmely
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  Lipopolysaccharides (LPS) of oral black-pigmented bacteria induce tumor necrosis factor production by LPS-refractory C3H/HeJ macrophages in a way different from that of Salmonella LPS.

Authors:  T Kirikae; T Nitta; F Kirikae; Y Suda; S Kusumoto; N Qureshi; M Nakano
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

7.  LPS-induced formation of immunoproteasomes: TNF-α and nitric oxide production are regulated by altered composition of proteasome-active sites.

Authors:  Julia Reis; Xiu Qin Guan; Alexei F Kisselev; Christopher J Papasian; Asaf A Qureshi; David C Morrison; Charles W Van Way; Stefanie N Vogel; Nilofer Qureshi
Journal:  Cell Biochem Biophys       Date:  2011-06       Impact factor: 2.194

8.  Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin.

Authors:  D Heumann; Y Adachi; D Le Roy; N Ohno; T Yadomae; M P Glauser; T Calandra
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

9.  Differential expression of caveolin-1 in lipopolysaccharide-activated murine macrophages.

Authors:  M G Lei; D C Morrison
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

10.  Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies.

Authors:  C R Amura; R Silverstein; D C Morrison
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.